跳至主要内容
临床试验/NL-OMON29915
NL-OMON29915已完成不适用

A Clinical Evaluation of the XIENCE TM V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Coronary Artery Lesions - SPIRIT V

Abbott0 个研究点目标入组 225 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Abbott
入组人数
225

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Maximum of one, de novo, target lesion per native major epicardial vessel or side branch (no prior stent implant, no prior brachytherapy
  • Target vessel reference diameter must be between 2.5 mm and 4.0 mm by visual estimate
  • Target lesion <28 mm in length by visual estimation
  • Target lesion must be in a major artery or branch with a visually estimated stenosis of >50% and <100% and a TIMI flow>1
  • Spirit V Registry: According tot he instructions for Use (IFU)

排除标准

  • Patient has had a known diagnosis of acute myocardial infarction within 72 hours preceding the index procedure
  • Patient has current unstable arrhythmias
  • Patient has a known left ventricular ejection fraction <30%
  • Spirit V Registry: According to the instructions for Use (IFU)

研究者

发起方
Abbott

相似试验